As CD39 is constitutively expressed on endothelial cells in order to maintain blood fluidity (30), using a cell-specific anti-CD39 Nb approach would preserve endothelial CD39 enzymatic activity while blocking CD39 on cells relevant for anti-tumor therapy. This evidence concerns the gene ENTPD1 and neoplasm.